箭头制药（NASDAQ:ARWR）创下一年新高 - 事情经过

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $31.14 and last traded at $30.82, with a volume of 610791 shares trading hands. The stock had previously closed at $29.13.

Wall Street Analyst Weigh In

• Want Diversified Upside in Biotechnology? Check out LABU

A number of research analysts have recently weighed in on ARWR shares. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Royal Bank Of Canada lowered their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $43.14.

View Our Latest Analysis on ARWR

Arrowhead Pharmaceuticals Stock Performance

The company has a market capitalization of $4.31 billion, a P/E ratio of -24.33 and a beta of 1.00. The firm has a 50 day moving average price of $20.67 and a two-hundred day moving average price of $16.76. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) EPS. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 15,000 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $30.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. The trade was a 6.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 40,000 shares of company stock valued at $1,025,000. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Exchange Traded Concepts LLC lifted its holdings in Arrowhead Pharmaceuticals by 31.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock worth $627,000 after buying an additional 11,879 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Arrowhead Pharmaceuticals during the 1st quarter worth $173,000. GAMMA Investing LLC lifted its holdings in Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,628 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock worth $1,890,000 after buying an additional 9,593 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 117.8% during the 1st quarter. Principal Financial Group Inc. now owns 629,075 shares of the biotechnology company's stock worth $8,014,000 after buying an additional 340,191 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Stories

• Five stocks we like better than Arrowhead Pharmaceuticals
• How to Choose Top Rated Stocks
• The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?
• What is the S&P 500 and How It is Distinct from Other Indexes
• Bloom Energy Booms on AI Power Demand and Analyst Upgrades
• Growth Investing: Should You Adopt This Investing Strategy in 2022?
• New Catalysts Build Positive Pressure on Intel Stock

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here